Tranilast

Drug Profile

Tranilast

Alternative Names: MK 341; NU3450; Rizaben; SB 252218

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; Nuon Therapeutics
  • Class Anthranilic acids; Antiallergics; Antiasthmatics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Collagen inhibitors; Immunomodulators; Mast cell stabilisers; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-myc modulators; SLC2A9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Asthma; Atopic dermatitis; Hypertrophic scars; Keloids
  • Discontinued Cancer metastases; Coronary artery restenosis; Hyperuricaemia; Multiple sclerosis; Rheumatoid arthritis; Vascular restenosis

Most Recent Events

  • 31 Dec 2010 Nuon Therapeutics completes a phase II trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Germany, Mexico, Serbia & United Kingdom
  • 28 May 2010 Tranilast is still in phase II trials for Rheumatoid arthritis worldwide except Japan and South Korea (http://www.kissei.co.jp/e_contents/relation/pipeline.html)
  • 24 Jul 2007 Kissei Pharmaceutical and Nuon Therapeutics enter into a licensing, supply and collaboration agreement for tranilast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top